DGAP-News: MagForce AG

DGAP-News: MagForce AG participates in four upcoming international conferences in Q4 2016

DGAP-News: MagForce AG / Key word(s): Conference MagForce AG participates in four upcoming international conferences in Q4 2016

27.10.2016 / 08:30 The issuer is solely responsible for the content of this announcement.

---------------------------------------------------------------------------

MagForce AG participates in four upcoming international conferences in Q4 2016

Berlin, Germany and Nevada, USA, October 27, 2016 - MagForce AG (Frankfurt, Entry Standard, Xetra: MF6, ISIN: DE000A0HGQF5), a leading medical device company in the field of nanomedicine focused on oncology, today announced its participation in four upcoming scientific and investor conferences in the fourth quarter 2016:

- 13th AIO Autumn Convention - Oncology in Internal Medicine Working Group (AIO) - Update Medical Oncology

Date: November 17-19, 2016 Location: Berlin, Germany Booth: No. 24, level 1

- 21st Annual Scientific Meeting and Education Day of the Society for Neuro-Oncology (SNO)

Date: November 17-20, 2016 Location: Scottsdale, Arizona, USA Presentation: "Inflammatory response after modified NanoTherm(R) and radiotherapy of recurrent glioblastoma" Presenter: Team of Prof. Dr. med. Walter Stummer, Director of the Clinic for Neurosurgery, University Hospital Münster Speaker: Dr. Dr. med. Oliver Grauer, Head of Neuro-Oncology Team, University Hospital Münster Date of presentation: Friday, November 18, 2016; Poster session 19:00 MST

- German Equity Forum

Date: November 21-23, 2016 Location: Frankfurt, Germany Presentation: Ben J. Lipps, CEO of MagForce AG, Monday, November 21, 2016, 14:00 CET Room: Oslo

- NOA Winter School 2016 - Neurological Working Group

Date: December 1-2, 2016 Location: Münster, Germany Presentation: "Local Hyperthermia as an adjuvant for malignant glioblastoma - NanoTherm and NanoPaste" Speaker: Dr. med. Johannes Wölfer, Deputy Director of the Neurosurgical Department, Clinic and Policlinic for Neurosurgery, University Hospital Münster Date of presentation: Thursday, December 1, 2016, 15:00 CET

About MagForce AG and MagForce USA, Inc.

MagForce AG, listed in the entry standard of the Frankfurt Stock Exchange (MF6, ISIN: DE000A0HGQF5), together with its subsidiary MagForce USA, Inc. is a leading medical device company in the field of nanomedicine focused on oncology. The Group's proprietary NanoTherm(TM) therapy enables the targeted treatment of solid tumors through the intratumoral generation of heat via activation of superparamagnetic nanoparticles. Mithril Capital Management, a growth-stage technology fund founded by Ajay Royan and Peter Thiel, along with MagForce AG, are investors and strategic partners in MagForce USA, Inc.

NanoTherm(TM), NanoPlan(R), and NanoActivator(R) are components of the therapy and have received EU-wide regulatory approval as medical devices for the treatment of brain tumors. MagForce, NanoTherm(TM), NanoPlan, and NanoActivator(R) are trademarks of MagForce AG in selected countries.

For more information, please visit: www.magforce.com

Get to know our Technology: video (You Tube)

Stay informed and subscribe to our mailing list





For meeting arrangements or any further questions, please contact us at:

Patient Advocacy

Dr. Katarzyna Zarychta +49 30 95 477 95-66 kzarychta@magforce.com

Medical Liaison

Dr. Ulrike Boettcher +49 89 95 477 95-64 uboettcher@magforce.com

Media & Investors

Barbara v. Frankenberg +49 30 30 83 80-77 bfrankenberg@magforce.com



Disclaimer

This release may contain forward-looking statements and information which may be identified by formulations using terms such as "expects", "aims", "anticipates", "intends", "plans", "believes", "seeks", "estimates" or "will". Such forward-looking statements are based on our current expectations and certain assumptions, which may be subject to a variety of risks and uncertainties. The results actually achieved by MagForce AG may substantially differ from these forward-looking statements. MagForce AG assumes no obligation to update these forward-looking statements or to correct them in case of developments, which differ from those, anticipated.





Contact: Barbara von Frankenberg Vice President Communications & Investor Relations

T +49-30-308380-77 E-Mail: bfrankenberg@magforce.com

---------------------------------------------------------------------------

27.10.2016 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG. The issuer is solely responsible for the content of this announcement.

The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Archive at www.dgap.de

---------------------------------------------------------------------------

Language: English Company: MagForce AG Max-Planck-Straße 3 12489 Berlin Germany Phone: +49 (0)30 308 380 0 Fax: +49 (0)30 308 380 99 E-mail: info@magforce.com Internet: www.magforce.com ISIN: DE000A0HGQF5 WKN: A0HGQF Listed: Regulated Unofficial Market in Berlin, Dusseldorf, Stuttgart, Tradegate Exchange; Open Market (Entry Standard) in Frankfurt End of News DGAP News Service ---------------------------------------------------------------------------

514847 27.10.2016